WO2002038769A3 - Für expression in eukaryonten optimierte hpv 16-l1 und hpv 16-l2 kodierende dna-sequenzen - Google Patents
Für expression in eukaryonten optimierte hpv 16-l1 und hpv 16-l2 kodierende dna-sequenzen Download PDFInfo
- Publication number
- WO2002038769A3 WO2002038769A3 PCT/DE2001/003618 DE0103618W WO0238769A3 WO 2002038769 A3 WO2002038769 A3 WO 2002038769A3 DE 0103618 W DE0103618 W DE 0103618W WO 0238769 A3 WO0238769 A3 WO 0238769A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hpv
- dna sequences
- optimised
- eukaryotic
- code
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
- C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Abstract
Beschrieben werden hinsichtlich der Codon-Verwendung optimierte DNA-Sequenzen, die ein HPV 16-Kapsidprotein L1 bzw. HPV 16-Kapsidprotein L2 kodieren. Diese DNA-Sequenzen umfassen die in den Figuren 5, 6 oder 7 gezeigten DNA-Sequenzen oder Fragmente oder Varianten dieser DNA-Sequenzen und erlauben die einfache rekombinante Herstellung von HPV 16-L1- bzw. L2-Kapsidproteinen oder Fragmenten davon mit hoher Ausbeute unter Vermeidung der Verwendung viraler Vektoren, vorzugsweise zur Herstellung von Vakzinen.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002213806A AU2002213806A1 (en) | 2000-11-09 | 2001-09-19 | Dna sequences, which code for optimised eukaryotic hpv 16-l1 and hpv 16-l2 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10055545.4 | 2000-11-09 | ||
DE10055545A DE10055545A1 (de) | 2000-11-09 | 2000-11-09 | Für Expression in Eukaryonten optimierte HPV 16-L1 und HPV 16-L2 kodierende DNA Sequenzen |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002038769A2 WO2002038769A2 (de) | 2002-05-16 |
WO2002038769A3 true WO2002038769A3 (de) | 2003-01-09 |
Family
ID=7662695
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DE2001/003618 WO2002038769A2 (de) | 2000-11-09 | 2001-09-19 | Für expression in eukaryonten optimierte hpv 16-l1 und hpv 16-l2 kodierende dna-sequenzen |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU2002213806A1 (de) |
DE (1) | DE10055545A1 (de) |
WO (1) | WO2002038769A2 (de) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1290859C (zh) * | 2001-08-31 | 2006-12-20 | 开普敦大学 | 关于hpv-11和hpv-16l1衣壳蛋白的载体,构建体,和转基因植物 |
KR20060003903A (ko) * | 2003-05-05 | 2006-01-11 | 이스티투토 디 리세르쉐 디 비올로지아 몰레콜라레 피. 안젤레티에스.피.에이. | 사람 암배아 항원을 암호화하는 합성 유전자 및 이의 용도 |
US8188244B2 (en) | 2004-02-11 | 2012-05-29 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Carcinoembryonic antigen fusions and uses thereof |
WO2008026869A1 (en) | 2006-08-28 | 2008-03-06 | Sungkyunkwan University Foundation For Corporate Collaboration | A dna vaccine for treating or preventing cervical cancer comprising a gene encoding hpv protein |
KR101588413B1 (ko) * | 2007-11-23 | 2016-02-02 | 상하이 제런 바이오테크놀러지 코포레이션 리미티드 | 인간 파필로마 바이러스의 주요 캡시드 단백질 l1을 암호화하는 유전자 및 이의 용도 |
BR102019025802A2 (pt) | 2019-12-05 | 2022-01-18 | Instituto Butantan | Processo de produção de uma composição imunológica de dna profilática e terapêutica contra hpv e cânceres associados ao vírus, proteína híbrida, vetor de expressão, composição imunológica e seus usos |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994012632A1 (en) * | 1992-11-27 | 1994-06-09 | University College London | Improvements in nucleic acid synthesis by pcr |
WO1999002694A1 (en) * | 1997-07-09 | 1999-01-21 | The University Of Queensland | Nucleic acid sequence and method for selectively expressing a protein in a target cell or tissue |
WO1999018220A1 (en) * | 1997-10-06 | 1999-04-15 | Loyola University Of Chicago | Papilloma virus capsomere vaccine formulations and methods of use |
CA2229955A1 (en) * | 1998-02-20 | 1999-08-20 | Medigene Gmbh | Papilloma virus capsomere vaccine formulations and methods of use |
WO2000014244A2 (en) * | 1998-09-04 | 2000-03-16 | Connaught Laboratories Limited | Treatment of cervical cancer |
US6114148A (en) * | 1996-09-20 | 2000-09-05 | The General Hospital Corporation | High level expression of proteins |
WO2001014416A2 (en) * | 1999-08-25 | 2001-03-01 | Merck & Co., Inc. | Synthetic papillomavirus genes optimized for expression in human cells |
-
2000
- 2000-11-09 DE DE10055545A patent/DE10055545A1/de not_active Withdrawn
-
2001
- 2001-09-19 WO PCT/DE2001/003618 patent/WO2002038769A2/de active Application Filing
- 2001-09-19 AU AU2002213806A patent/AU2002213806A1/en not_active Abandoned
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994012632A1 (en) * | 1992-11-27 | 1994-06-09 | University College London | Improvements in nucleic acid synthesis by pcr |
US6114148A (en) * | 1996-09-20 | 2000-09-05 | The General Hospital Corporation | High level expression of proteins |
US6114148C1 (en) * | 1996-09-20 | 2012-05-01 | Gen Hospital Corp | High level expression of proteins |
WO1999002694A1 (en) * | 1997-07-09 | 1999-01-21 | The University Of Queensland | Nucleic acid sequence and method for selectively expressing a protein in a target cell or tissue |
WO1999018220A1 (en) * | 1997-10-06 | 1999-04-15 | Loyola University Of Chicago | Papilloma virus capsomere vaccine formulations and methods of use |
CA2229955A1 (en) * | 1998-02-20 | 1999-08-20 | Medigene Gmbh | Papilloma virus capsomere vaccine formulations and methods of use |
WO2000014244A2 (en) * | 1998-09-04 | 2000-03-16 | Connaught Laboratories Limited | Treatment of cervical cancer |
WO2001014416A2 (en) * | 1999-08-25 | 2001-03-01 | Merck & Co., Inc. | Synthetic papillomavirus genes optimized for expression in human cells |
Non-Patent Citations (13)
Title |
---|
DATABASE EMBL [online] 16 August 2001 (2001-08-16), XP002202897, retrieved from EBI Database accession no. AJ313180 * |
DATABASE EMBL [online] 16 August 2001 (2001-08-16), XP002202898, retrieved from EBI Database accession no. AJ313181 * |
DATABASE EMBL [online] 16 August 2001 (2001-08-16), XP002202899, retrieved from EBI Database accession no. AJ313179 * |
DATABASE EMBL [online] 18 June 1997 (1997-06-18), XP002202894, retrieved from EBI Database accession no. AF001600 * |
DATABASE EMBL [online] 5 December 2000 (2000-12-05), XP002202896, retrieved from EBI Database accession no. AF322411 * |
DATABASE EMBL [online] 5 December 2000 (2000-12-05), XP002202900, retrieved from EBI Database accession no. AF322413 * |
DATABASE GSN [online] 14 March 2000 (2000-03-14), retrieved from EBI Database accession no. AAZ48174 * |
DATABASE GSN [online] 14 May 2001 (2001-05-14), retrieved from EBI Database accession no. AAF75383 * |
DATABASE GSP [online] 14 March 2000 (2000-03-14), retrieved from EBI Database accession no. AAY57720 * |
DATABASE SWALL [online] 21 July 1986 (1986-07-21), XP002202895, retrieved from EBI Database accession no. P03107 * |
LEDER C ET AL: "Enhancement of capsid gene expression: preparing the human papillomavirus type 16 major structural gene L1 for DNA vaccination purposes.", JOURNAL OF VIROLOGY. UNITED STATES OCT 2001, vol. 75, no. 19, October 2001 (2001-10-01), pages 9201 - 9209, XP002202893, ISSN: 0022-538X * |
SEEDORF K ET AL: "HUMAN PAPILLONMAVIRUS TYPE 16 DNA SEQUENCE", VIROLOGY, RAVEN PRESS, NEW YORK, NY, US, vol. 145, no. 1, U89348, 1 August 1985 (1985-08-01), pages 181 - 185, XP002059799, ISSN: 0042-6822, Retrieved from the Internet <URL:EBI> * |
ZHOU JIAN ET AL: "Papillomavirus capsid protein expression level depends on the match between codon usage and tRNA availability", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 73, no. 6, June 1999 (1999-06-01), pages 4972 - 4982, XP002164427, ISSN: 0022-538X * |
Also Published As
Publication number | Publication date |
---|---|
WO2002038769A2 (de) | 2002-05-16 |
DE10055545A1 (de) | 2002-07-25 |
AU2002213806A1 (en) | 2002-05-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002014358A3 (en) | Novel secreted proteins and their uses | |
WO2002008277A3 (en) | Nucleic acids, vectors, host cells, polypeptides, and uses thereof | |
CA2158455A1 (en) | Immunogenic chimeras comprising nucleic acid sequences encoding endoplasmic reticulum signal sequence peptides and at least one other peptide and their uses in vaccines and disease treatments | |
WO2002062296A3 (en) | Methods and compositions useful for stimulating an immune response | |
WO2001021807A8 (en) | Hepatitis c virus envelope two protein (e2) which lacks all or part of the hypervariable region one (hvr1), corresponding nucleic acids, chimeric viruses and uses thereof | |
WO2003060072A3 (en) | Recombinant polypeptides | |
WO2001032882A3 (en) | Nucleic acids and proteins from group b streptococcus | |
WO2002070549A3 (en) | Chimeric polypeptides of serum albumin and uses related thereto | |
EP1613345A4 (de) | Zusammensetzungen und verfahren mit dem respiratory syncytial virus untergruppe b stamm 9320 | |
WO2002038769A3 (de) | Für expression in eukaryonten optimierte hpv 16-l1 und hpv 16-l2 kodierende dna-sequenzen | |
WO2002027007A3 (en) | Production of viral vectors | |
ATE424409T1 (de) | Chimere human papilloma virus 16 l1 proteine, welche ein l2 peptid enthalten, damit hergestellte virus-ähnliche partikel und methode zur herstellung der partikel | |
WO2002070665A8 (en) | Recombinant hybrid allergen constructs with reduced allergenicity that retain immunogenicity of the natural allergen | |
WO2002032939A3 (en) | Secreted proteins and their uses | |
WO2002090500A3 (en) | Novel human proteins, polynucleotides encoding them and methods of using the same | |
WO2002026801A3 (en) | Secreted proteins and their uses | |
WO2004087886A3 (en) | Modified adenoviral e1a constructs and methods of use thereof | |
WO2002016578A3 (en) | Secreted proteins and methods of using same | |
WO2001049712A3 (en) | Vaccine against isav (infectious salmon anaemia virus) | |
WO2002048361A3 (en) | Novel secreted proteins and their uses | |
WO1998042847A3 (de) | Papillomvirus-hauptcapsid-proteins und deren verwendung in diagnose, therapie und vakzinierung | |
PT1383796E (pt) | Estirpe neurovirulenta do vírus do nilo ocidental e as suas aplicações | |
PL346012A1 (en) | Recombinant virus expressing foreign dna encoding feline cd80, feline ctla-4 or feline cd86 and uses thereof | |
WO2002002771A3 (en) | Human sparc-homologous (hsparc-h1) gene and methods and uses thereof | |
WO2002046408A3 (en) | Human proteins, polynucleotides encoding them and methods of using the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |